How Pharmather is Using Human Organoid Models for Research in the Psychedelic Space

Name: How Pharmather is Using Human Organoid Models for Research in the Psychedelic Space
Uploaded: 2020-10-29
Channel: Shadd Dales
Description: In Part #2 of our interview with Pharmather (CSE: PHRM) CEO Fabio Chianelli we discuss how the company has carved out their own niche through FDA approved type psychedelics that focus on Ketamine, and where they position themselves amongst other comp

By Shadd Dales On Oct 29, 2020

In Part #2 of our interview with Pharmather (CSE: PHRM) CEO Fabio Chianelli we discuss how the company has carved out their own niche through FDA approved type psychedelics that focus on Ketamine, and where they position themselves amongst other companies within the psychedelic space.

In addition, through their research Pharmather is constructing their own internal data along with their partnership with the UHN. The data is developed through human organoid models using specific in vitro type methods.

Pharmather Inc., is a wholly subsidiary of Newscope Capital Corporation and a specialty life sciences company that focuses on the research and development of psychedelic pharmaceuticals.

The Dales Report Inc. disclosure policy applies to this post

#investing #ketamine #psilocybin #psychedelics #stockmarket

Shadd Dales

Shadd Dales is the Founder and President of The Dales Report and has an extensive background in the business media industry.

His work translates into over 15 years in mainstream media that included roles with BNN Bloomberg, CTV Properties and the iHeart Radio Network.

Shadd is considered one of the leading on air talents in both the cannabis and psychedelic space and has interviewed some of the most notable CEO names in the industry.

Shadd’s vision is to establish a content platform that is equivalent to a mainstream broadcast produced in a format that is relevant for today’s investor.